Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|5|539-545

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.5, 2010-01, pp. : 539-545

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 22, Iss. 16, 2016-05 ,pp. : 2349-2357

Bentham Science Publishers

Access to resources Recommend Favorite

Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia

By  

Current Cancer Drug Targets, Vol. 11, Iss. 7, 2011-09 ,pp. : 837-848

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Epigenetic Modifiers in Cancer

By  

Current Medicinal Chemistry, Vol. 14, Iss. 24, 2007-10 ,pp. : 2540-2547

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Topoisomerase I-Targeting Agents, Camptothecin Analogues

By  

Mini Reviews in Medicinal Chemistry, Vol. 2, Iss. 6, 2002-01 ,pp. : 611-619

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 807-807

Bentham Science Publishers

Access to resources Recommend Favorite